ERBB2 and triple-negative breast carcinoma: Among them, there were 328 cases (20.7%) of Luminal A, 883 cases (55.8%) of Luminal B, 184 cases (11.6%) of HER2 positive and 188 cases (11.9%) of triple negative breast cancer (TNBC).